Skip to main content

Table 1 Patient and donor characteristics

From: Haploidentical donor is preferred over matched sibling donor for pre-transplantation MRD positive ALL: a phase 3 genetically randomized study

CharacteristicsHaplo-SCT groupMSDT groupP value
Number of patients16939 
Median age (range), years24 (3–58)35 (9–60)0.001
Male sex, n (%)107 (63.3%)21 (53.8%)0.273
Diagnosis, n
 B-ALL  0.142
  Ph positive49 (29.0%)10 (25.6%) 
  Ph negative120 (55.0%)29 (69.2%) 
 T-ALL27 (16.0%)2 (5.1%) 
Disease status  0.328
 CR1131 (77.5%)33 (84.6%) 
 ≥ CR238 (22.5%)6 (15.4%) 
Median level of pre-transplant MRD (range)#0.07% (0.001–6.01%)0.05% (0.001–3.02%)0.581
Median time from diagnosis to transplant (months, range)6.5(3–72)6.0(3–192)0.803
Donor-recipient sex matched grafts, n (%)  0.314
 Male-male76 (45.0%)13 (33.3%) 
 Male-female44 (26.0%)10 (25.6%) 
 Female-male31 (18.3%)8 (20.5%) 
 Female-female18 (10.7%)8 (20.5%) 
Donor-recipient relationship, n (%)  NA
 Father-child80 (47.3%)0 
 Mother-child12 (7.1%)0 
 Sibling-sibling48 (28.4%)39 (100%) 
 Child-parent24 (14.2%)0 
 Other5 (3.0%)0 
ABO matched grafts, n (%)  0.414
 Matched98 (58.0%)19 (48.7%) 
 Major mismatch30 (17.8%)8 (20.5%) 
 Minor mismatch33 (19.5%)11 (28.2%) 
 Bi-directional mismatch8 (4.7%)1 (2.6%) 
Cell compositions in grafts, mean (range)   
 Infused nuclear cells, 108/kg8.16 (5.53–15.67)8.14 (5.32–13.14)0.711
 Infused CD34+ cells, 106/kg2.24 (0.82–8.07)2.45 (0.79–6.39)0.111
Intervention for positive MRD post-HSCT among all patients, n (%)39 (21%)16 (41%)0.027
Intervention among positive MRD post-HSCT patients, n (%)39/45 (87%)16/17(94%)0.662
Intervention methods among positive MRD post-HSCT patients, n (%)  0.833
 Interferon-α29 (64%)11 (65%) 
 Donor lymphocyte infusion6 (13%)3 (18%) 
 Targeted drug4 (9%)2 (12%) 
 No intervention6 (13%)1 (6%) 
  1. The percentages of total patients either in Haplo-SCT group or MSDT group
  2. Haplo-SCT haploidentical stem cell transplantation, MSDT human leukocyte antigen-matched sibling donor transplantation, ALL acute lymphoblastic leukemia, Ph Philadelphia-chromosome, CR complete remission, MRD minimal (measurable) residual disease, MA myeloablative conditioning regimen, NS no significance, DLI donor lymphocyte infusions
  3. #Indicate the percentages of MRD in total nuclear cells of bone marrow detected by multiparameter flow cytometry